To determine if patients with high risk disease have a longer survival time with standard treatment (hormone treatment and radiotherapy) versus standard treatment with the addition of 24 months of TAK-700.
Must be enrolled within 180 days of diagnosis.
No testosterone use for 90 days before enrollment. No prior radiation or chemotherapy. No previous hormone treatment. No previous cardiac history.